Lee Pharmaceuticals, Inc. (AIMN)
| Market Cap | 6.00 -82.9% |
| Revenue (ttm) | n/a |
| Net Income | -505.11K |
| EPS | n/a |
| Shares Out | 587.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,975,030 |
| Open | 0.0100 |
| Previous Close | 0.0070 |
| Day's Range | 0.0035 - 0.0100 |
| 52-Week Range | 0.0031 - 11.9760 |
| Beta | 943.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Lee Pharmaceuticals
Lee Pharmaceuticals, Inc. provides personal care products in the United States. The company offers aloe vera products, antacids, cosmetics and douches, cough and cold products, depilatories and waxes, laxatives, lip balm products, men’s personal care products, monticello drugs, oral care products, pain relievers, skin care products, tobacco accessories, topical ointments and creams, baby care products, and vitamins and nutritional products, as well as nasal sprays, lip conditioners, and over the counter products. It also provides private label ... [Read more]
News
AIMN: As Healthcare Breaches Hit a Record and Move to Third-Party Providers, AimwellBio.com Explores a Redundancy Layer Built to Survive the Vendor
With over one billion Americans' health records now breached and the largest incidents shifting to mission-critical third parties, Aimwell Partners Inc. is exploring verified infrastructure that adds ...
AimwellBio Expands Platform Capabilities to Strengthen the Infrastructure Behind Trusted Healthcare Intelligence
DENVER, CO / ACCESS Newswire / June 17, 2026 / Aimwell Partners Inc. (OTCID:AIMN) today announced an expansion of technical capabilities supporting AimwellBio, the Company's healthcare intelligence pl...
AimwellBio Opens Verified Observer Network to Healthcare, Research, and Capital Professionals at No Cost
Aimwell Partners Inc. (OTCID:AIMN) expands Observer access, a credentialed professional intelligence network for biopharma, inviting doctors, scientists, regulatory professionals, and capital allocato...
The Question No Telehealth Underwriter Wants Asked: When was Your Platform Last Breached, and Would You Even Know?
Aimwell Partners Inc. (OTC:AIMN) advances a verified collaboration mesh for healthcare intelligence, built on identity, encryption, and chain-of-custody integrity rather than the legacy internet infra...
As Healthcare's Software Leaders Race to Add AI, AimwellBio.com Moves to Build the Layer That Verifies It
Aimwell Partners Inc. explores verified biomedical intelligence infrastructure, positioning verification as the next essential layer in a proven, multi-billion-dollar medical software ecosystem DENVER...
AimwellBio Opens a Door Most People Will Not Be Allowed Through, And Healthcare's Sharpest Professionals Are Already Walking In
A new professional intelligence network is forming around the people who shape clinical, research, regulatory, and capital decisions. Observer access is free.
Why a Verified Biopharma Intelligence Network Is Quietly Becoming the Credential Itself
DENVER, CO / ACCESS Newswire / May 27, 2026 / Aimwell Bio (OTC:AIMN) today issued commentary on what the company believes is an emerging shift within healthcare and biopharma infrastructure: the rise ...
The Quiet Restructuring of Healthcare Intelligence: Why the Industry is Moving Toward Verified Professional Networks Over Anonymous AI
DENVER, CO / ACCESS Newswire / May 20, 2026 / Aimwell Partner, (OTC:AIMN) and it's brand, AimwellBio today released the following industry brief examining the growing shift within healthcare toward ve...
Inside AimwellBio's Federated Health Intelligence Network: Verified Clinical Intelligence Model Gains Attention Among Physicians
DENVER, CO / ACCESS Newswire / May 18, 2026 / AimwellBio, operating through Aimwell Partners Inc. (OTCID:AIMN), appears to have structured its platform architecture around a question increasingly bein...
The Doctors Saw It First. Then the Chiropractors Asked.
DENVER, CO / ACCESS Newswire / May 13, 2026 / Aimwell Partners Inc. (OTCID:AIMN) today confirmed the next phase of expansion across the AimwellBio verified intelligence platform: new indication covera...
Aimwell Partners Brand, AimwellBio Announces Expanded FHIN Intelligence Framework, Early Demo Feedback, and New AIMN Development Milestones
DENVER, CO / ACCESS Newswire / May 11, 2026 / Aimwell Partners (OTCID:AIMN) Brand, AimwellBio announced continued progress across its live demonstration, onboarding, and framework development initiati...
While You Were in That Meeting, 14 Signals Moved. Your Competitors Saw Them.
AimwellBio's live signal intelligence engine is now tracking 13 source streams in real time - FDA actions, drug recalls, clinical trials, patent filings, global outbreaks, and regulatory divergence. I...
AimwellBio Reports Strong Early Demand From Hospital Systems and Researchers as FHIN Founding Cohort Takes Shape
NEW YORK CITY, NY / ACCESS Newswire / May 4, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today announced that initial engagement with hospital systems and hospitalists has...
AimwellBio Launches Verified Intelligence Layer for Healthcare as AI Hallucination Risk Reaches Clinical Settings
Aimwell Partners Inc. (OTC:AIMN) expands its healthcare intelligence platform to address one of the fastest-growing risks in modern medicine - clinical decisions influenced by unverified or AI-generat...
Aimwell Bio Expands FHIN Deployment Across U.S. and Australia as Clinical Leaders Move to Replace Unverified AI Hospitalists and Physician Groups Drive Demand for Source-Traceable Intelligence Infrastructure
MIAMI, FL / ACCESS Newswire / April 22, 2026 / Aimwell Partners (OTC pink:AIMN) Aimwell Bio today announced a material expansion of engagement across the healthcare ecosystem, with active deployment d...
Aimwell Bio Announces "Founding Cohort" of Federated Health Intelligence Network (FHIN); Tackles 38% AI Hallucination Rate in Biopharma
MIAMI, FL / ACCESS Newswire / April 20, 2026 / Aimwell Partners (OTC Pink:AIMN) Aimwell Bio today officially opened applications for its exclusive Founding Cohort, a high-fidelity intelligence network...
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement w...
Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investig...
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
BEIJING , Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon...
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mell...
RONN Inc. Advances Hydrogen Logistics and Hub Strategy in Barbados as Saudi JV Ignites Cross-Regional Acceleration
SCOTTSDALE, AZ / ACCESS Newswire / May 21, 2025 / RONN Inc. (OTC PINK:RONN), the U.S.-based hydrogen mobility pioneer, announced today that its long-developing Barbados hydrogen logistics and fueling ...
RONN Inc. Accelerates Global Hydrogen Manufacturing Initiative Amid Rising Diplomatic Engagement in Brazil and the U.K.
SCOTTSDALE, ARIZONA / ACCESS Newswire / May 15, 2025 / RONN Inc. (OTC:RONN), the U.S.-based pioneer in hydrogen mobility platforms, announced today that CEO Ronn Ford will travel to Ceará, Brazil, in ...
Budget Approval Expected Saturday for RONN Inc.-Saudi Arabia Hydrogen Joint Venture
RIYADH, SAUDI ARABIA AND SCOTTSDALE, AZ / ACCESS Newswire / May 1, 2025 / RONN Inc. (OTC PINK:RONN), a U.S.-based hydrogen technology innovator, announced today that it will meet with its Saudi Arabia...
RONN Inc. Initiates Plans For Riyadh Headquarters To Launch “RONN Saudi Arabia” Joint Venture, Advancing Vision 2039 Hydrogen Initiatives
SCOTTSDALE, AZ / ACCESS Newswire / April 24, 2025 / RONN Inc. (OTC PINK:RONN), a U.S.-based hydrogen technology innovator, announces that it is establishing a new corporate office in Riyadh, Saudi Ara...
Ronn Inc. Highlights Saudi Arabia's Hydrogen Momentum and Vision 2030 Alignment Amid Strategic Joint Venture Talks
SCOTTSDALE, AZ / ACCESS Newswire / April 11, 2025 / Following its recently announced Phase One Strategic Agreement in the Kingdom of Saudi Arabia, Ronn Inc. (OTC PINK:RONN) is releasing an executive o...